Navigation Links
Heightened Security Threats and Economic Issues Provide Fillip to Global Civil and Military Biometrics Market, Says Frost & Sullivan
Date:3/21/2012

migration. Biometric passports are on their way to being universally adopted; North America and Europe have already led the way, with the rest of the world expected to follow.

While offering several benefits, slow return on investment (ROI) and high initial investment costs are the main restraints to the widespread uptake of biometric technologies. Projects related to universal census or the issuance of eIDs might result in extremely high costs due to sheer volumes. Another crucial aspect restraining the adoption of biometrics are concerns related to privacy as well as lengthy sales cycles in governments.

"While the ROI may not be visible at the very outset, nevertheless, once the technology is in place, faster verification and portable devices will decrease the amount of travel required, which will be beneficial in the long-run," remarks Rutkowski. "Privacy is the main hindrance in biometric government programmes; detractors believe that this type of identity verification can be offensive, distasteful, invasive, or simply embarrassing."

As the market gathers momentum, becoming a recognisable participant will be crucial since the majority of customers are governments.

"Becoming more significant through the acquisition of competitors will not only positively influence a company's market share but will support an enhanced position on the international markets," concludes Rutkowski. "Acquiring a foreign company may decrease the affect of protectionism by certain governments."

If you are interested in more information on this study, please send an e-mail with your contact details to Joanna Lewandowska, Corporate Communications, at joanna.lewandowska@frost.com.

Global Civil and Military Biometrics Market Assessment is part of the Defence Growth Partnership Services programme, which also includes research in the following markets: United Kingdom Civil Security Market
'/>"/>

SOURCE Frost & Sullivan
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. BIO-key(R) to Showcase Biometric Security Applications at 2008 Biometric Technology Expo
2. Frost & Sullivan Recognizes AOptix Technologies for its Pioneering Contribution to Security through Noninvasive Biometrics
3. Sig-Tec(R) and BIO-key(R) Deliver Advanced Biometric Security Solution to Ohio County Law Enforcement Agency
4. World Food Day brings attention to food security around the globe
5. BIO-key(R) Granted Additional Patent for Biometric Security Solution
6. bioMETRX, Inc. Welcomes Residential and Commercial Security Expert to Board of Directors
7. Research conference at UH to focus on US troops needs, homeland security
8. USAID grant awarded to improve food security in Africa
9. Springer launches Food Security
10. Halas wins high-profile national security award
11. Nuclear science for food security
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... biologists, led by Clemson University associate professor Andrew S. ... will pave the way for novel anti-fouling paint for ... and industrial applications. , The team,s findings, published in ... larval stage of barnacles that attaches to a wide ... material that acts as an underwater heavy-duty adhesive. , ...
(Date:7/30/2014)... Portland Press Limited today announced an across-the-board increase ... , The 2013 InCites Journal Citation Reports (Thomson ... Biochemical Journal , Essays in Biochemistry ... Bioscience Reports all received increases in their ... Biochemical Society and published by Portland Press Limited. ...
(Date:7/30/2014)... A professor from Wayne State University,s College of ... National Science Foundation for the project, "Nanoparticle-directed synthesis ... National Science Foundation, nanotechnology is the creation and ... novel properties and functions. A major bottleneck in ... methods that connect different functional materials into one ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... have created the first three-dimensional living tissue model, complete ... therapeutics to combat brain tumors. The 3-D model gives ... tissue cultures. The researchers created a glioma, or ... surrounds it. In a series of experiments, the team ...
... have succeeded in changing the genetic material of cancer ... in nanosurgery opens the door to new medical applications, ... A light scalpel to treat cancerous cells, The ... team uses a femtosecond laser (a laser with ultra-short ...
... Resolving the world,s major challenges whether climate change, ... scarcity requires a sweeping shift in our approach ... leading scientists told European policy makers today during ... and Societal Challenges for our Unstable Earth" (RESCUE). ...
Cached Biology News:Researchers make living model of brain tumor 2Europe needs a 'RESCUE' revolution 2Europe needs a 'RESCUE' revolution 3
(Date:7/30/2014)... , July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... the Day 180 List of Outstanding Issues (LOI) from ... Human Use (CHMP) for the NB32 Marketing Authorization Application ... is an investigational drug candidate being evaluated for weight ... Day 120 time point were adequately addressed by the ...
(Date:7/30/2014)...  AtheroNova Inc. (OTCBB: AHRO), a biotech company ... to safely regress atherosclerotic plaque and improve lipid ... CardioNova, has accomplished first dosing of subjects for ... compound, AHRO-001.  This Phase 1b trial will be ... trial completed in February 2014, in which patients ...
(Date:7/30/2014)... July 30, 2014 Vala Sciences ... U.S. Environmental Protection Agency (EPA). This new contract ... toxicity models, including tests designed to assess the ... the formation of connections between neurons (synapses), which ... and synapse formation by environmental pollutants likely contributes ...
(Date:7/29/2014)... July 30, 2014 SoundConnect ... collaboration company, is proud to announce the strategic ... positions in their Boston, Charleston and Atlanta offices. ... the increased demand for hosted solutions, collaboration and ... and reduce cost. , SoundConnect was founded in ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2
... July 14 Bio-Optronics, Inc., a leader in healthcare workflow ... software solution that can simultaneously handle the most intricate scheduling ... staff schedules. , , Physician ... , Bio-Optronics President & CEO, ...
... , HALIFAX, NS, July 14 /PRNewswire/ - ImmunoVaccine ... entered into an agreement to exclusively license seven ... company. These proprietary antigens specifically target breast, ovarian ... antigens with its DepoVax(TM) delivery platform to develop ...
... , , TAMPA, Fla., July ... on the research and development of cancer immunotherapies, announces that the ... its dendritic cell therapy. , , ... I/II clinical trial testing the safety and efficacy of its immunotherapy ...
Cached Biology Technology:NEW Momentum(TM) Physician and Staff Scheduling Software for Imaging Centers, OB/GYN, and Other Specialty Practices Improves Productivity and Equity in Scheduling 2ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 3